Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study.
Tsuyoshi MatsumuraHiroya HashimotoMasahiro SekimizuAkiko M SaitoYasufumi MotoyoshiAkinori NakamuraSatoshi KuruTakayasu FukudomeKazuhiko SegawaToshiaki TakahashiTakuhisa TamuraTetsuo KomoriChigusa WatanabeMasanori AsakuraKoichi KimuraYuko IwataPublished in: Orphanet journal of rare diseases (2022)
Tranilast is safe and effective in inhibiting TRPV2 expression, even in MD patients with advanced heart failure. Further trials are needed to evaluate the efficacy of tranilast in preventing myocardial damage, heart failure, motor impairment, and respiratory failure. Clinical trial registration The study was registered in the UMIN Clinical Trials Registry (UMIN-CTR: UMIN000031965, URL: http://www.umin.ac.jp/ctr/ ) [March 30, 2018] and the Japan Registry of Clinical Trials (jRCT, registration number: jRCTs031180038, URL: https://jrct.niph.go.jp/ ) [November 12, 2021]. Patient registration was started in December 19, 2018.
Keyphrases
- clinical trial
- heart failure
- open label
- phase ii
- muscular dystrophy
- respiratory failure
- left ventricular
- phase iii
- study protocol
- acute heart failure
- poor prognosis
- cardiac resynchronization therapy
- extracorporeal membrane oxygenation
- double blind
- mechanical ventilation
- oxidative stress
- atrial fibrillation
- randomized controlled trial
- case report
- molecular dynamics
- duchenne muscular dystrophy
- squamous cell carcinoma
- phase ii study
- spinal cord injury
- acute respiratory distress syndrome
- long non coding rna
- binding protein